(0.29%) 5 146.50 points
(0.31%) 38 559 points
(0.38%) 17 914 points
(-0.85%) $83.14
(1.30%) $1.948
(-0.18%) $2 343.00
(0.15%) $27.58
(0.79%) $929.40
(-0.30%) $0.932
(-0.39%) $10.98
(-0.38%) $0.797
(0.25%) $92.11
Live Chart Being Loaded With Signals
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U...
Stats | |
---|---|
Dagens volum | 1.28M |
Gjennomsnittsvolum | 2.42M |
Markedsverdi | 185.90M |
EPS | $0 ( 2024-02-08 ) |
Neste inntjeningsdato | ( $-0.0600 ) 2024-05-09 |
Last Dividend | $0.0700 ( 2014-04-28 ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.810 |
ATR14 | $0.00400 (0.32%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-10-02 | Rankowitz Michael L | Buy | 90 000 | Common Stock Option |
2023-10-02 | Eisenberger Mario | Buy | 70 000 | Common Stock Option |
2023-10-02 | Lu Lucy | Buy | 80 000 | Common Stock Option |
2023-10-02 | Hyun Grace | Buy | 60 000 | Common Stock Option |
2023-05-09 | Greco Michele | Buy | 104 000 | Common Stock Option |
INSIDER POWER |
---|
94.71 |
Last 100 transactions |
Buy: 7 521 942 | Sell: 795 000 |
Volum Korrelasjon
Veru Inc Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
AGLE | 0.927 |
CNSP | 0.911 |
STER | 0.91 |
PRTK | 0.91 |
AZYO | 0.906 |
TCX | 0.895 |
TTGT | 0.894 |
HCDIP | 0.891 |
TFFP | 0.885 |
INTZ | 0.879 |
10 Mest negative korrelasjoner | |
---|---|
LWAC | -0.95 |
FANH | -0.894 |
AGFS | -0.892 |
IMRA | -0.883 |
TGLS | -0.867 |
PTMN | -0.864 |
USLB | -0.862 |
LYTS | -0.859 |
SLGN | -0.856 |
SEDG | -0.852 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Veru Inc Korrelasjon - Valuta/Råvare
Veru Inc Økonomi
Annual | 2023 |
Omsetning: | $16.30M |
Bruttogevinst: | $7.57M (46.43 %) |
EPS: | $-1.100 |
FY | 2023 |
Omsetning: | $16.30M |
Bruttogevinst: | $7.57M (46.43 %) |
EPS: | $-1.100 |
FY | 2022 |
Omsetning: | $39.35M |
Bruttogevinst: | $30.59M (77.73 %) |
EPS: | $-1.050 |
FY | 2021 |
Omsetning: | $61.26M |
Bruttogevinst: | $47.93M (78.24 %) |
EPS: | $0.100 |
Financial Reports:
No articles found.
Veru Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0500 | 2010-01-27 |
Last Dividend | $0.0700 | 2014-04-28 |
Next Dividend | $0 | N/A |
Payout Date | 2014-05-07 | |
Next Payout Date | N/A | |
# dividends | 18 | -- |
Total Paid Out | $1.040 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.68 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2010 | $0.200 | 4.14% |
2011 | $0.200 | 3.50% |
2012 | $0.230 | 4.87% |
2013 | $0.270 | 3.69% |
2014 | $0.140 | 1.67% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -4.05 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.801 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -2.14 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.21 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 2.58 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.44 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.133 | -1.500 | 7.78 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -36.67 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.591 | 2.00 | -0.197 | -0.394 | [0 - 30] |
freeCashFlowPerShareTTM | -0.595 | 2.00 | -0.298 | -0.595 | [0 - 20] |
debtEquityRatioTTM | 0.208 | -1.500 | 9.17 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.503 | 1.000 | 4.95 | 4.95 | [0.2 - 0.8] |
operatingProfitMarginTTM | -3.96 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -5.53 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.198 | 0.800 | -2.02 | -1.612 | [0.5 - 2] |
Total Score | -1.265 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -1.980 | 1.000 | -0.301 | 0 | [1 - 100] |
returnOnEquityTTM | -2.14 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.595 | 2.00 | -0.198 | -0.595 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.591 | 2.00 | -0.197 | -0.394 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.416 | 1.500 | -0.561 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -3.74 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.19 |
Veru Inc
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.